Vaccitech Virtual KOL Event
January 25, 2022
Management and leading experts will discuss VTP-300, as a key component of a potential functional cure for chronic hepatitis B (CHB) infection, as well as the broader HBV therapeutics landscape.
Vaccitech Plc [VACC] $106 MM MCap
Proprietary ChAdOx (prime) and MVA (boost) technology platform induces CD8+ T cell and antibody immune responses to treat and prevent infectious diseases and cancer. Broad therapeutic pipeline. Encouraging Ph1/2 interim efficacy data for VTP-300 (HBV functional cure) and VTP-200 (high-risk HPV therapeutic) efficacy data expected 4Q2022. $15M royalty revenue during Q42021 from AstraZeneca's commercial sales of Vaxzevria® (out-licensed ChAdOx COVID-19 vaccine) [more information]